Annual Total Liabilities
$235.21 M
+$70.03 M+42.40%
December 31, 2023
Summary
- As of February 12, 2025, MDGL annual total liabilities is $235.21 million, with the most recent change of +$70.03 million (+42.40%) on December 31, 2023.
- During the last 3 years, MDGL annual total liabilities has risen by +$188.19 million (+400.19%).
- MDGL annual total liabilities is now at all-time high.
Performance
MDGL Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$296.11 M
+$53.44 M+22.02%
September 30, 2024
Summary
- As of February 12, 2025, MDGL quarterly total liabilities is $296.11 million, with the most recent change of +$53.44 million (+22.02%) on September 30, 2024.
- Over the past year, MDGL quarterly total liabilities has increased by +$53.44 million (+22.02%).
- MDGL quarterly total liabilities is now at all-time high.
Performance
MDGL Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
MDGL Total Liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +42.4% | +22.0% |
3 y3 years | +400.2% | +22.0% |
5 y5 years | +2685.6% | +22.0% |
MDGL Total Liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +204.6% | at high | +285.0% |
5 y | 5-year | at high | +822.7% | at high | +1061.6% |
alltime | all time | at high | >+9999.0% | at high | +8702.3% |
Madrigal Pharmaceuticals Total Liabilities History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $296.11 M(+22.0%) |
Jun 2024 | - | $242.67 M(+4.8%) |
Mar 2024 | - | $231.52 M(-1.6%) |
Dec 2023 | $235.21 M(+42.4%) | $235.21 M(+9.0%) |
Sep 2023 | - | $215.72 M(+8.4%) |
Jun 2023 | - | $198.96 M(+9.1%) |
Mar 2023 | - | $182.31 M(+10.4%) |
Dec 2022 | $165.18 M(+113.9%) | $165.18 M(+11.6%) |
Sep 2022 | - | $147.97 M(+11.4%) |
Jun 2022 | - | $132.86 M(+72.7%) |
Mar 2022 | - | $76.92 M(-0.4%) |
Dec 2021 | $77.22 M(+64.2%) | $77.22 M(+10.6%) |
Sep 2021 | - | $69.82 M(+21.8%) |
Jun 2021 | - | $57.30 M(+16.5%) |
Mar 2021 | - | $49.18 M(+4.6%) |
Dec 2020 | $47.02 M(+84.5%) | $47.02 M(-5.8%) |
Sep 2020 | - | $49.91 M(+9.8%) |
Jun 2020 | - | $45.47 M(+75.0%) |
Mar 2020 | - | $25.98 M(+1.9%) |
Dec 2019 | $25.49 M(+201.9%) | $25.49 M(+60.3%) |
Sep 2019 | - | $15.90 M(+23.9%) |
Jun 2019 | - | $12.84 M(+16.1%) |
Mar 2019 | - | $11.05 M(+30.9%) |
Dec 2018 | $8.44 M(-16.0%) | $8.44 M(+27.1%) |
Sep 2018 | - | $6.64 M(+22.2%) |
Jun 2018 | - | $5.44 M(-13.6%) |
Mar 2018 | - | $6.29 M(-37.4%) |
Dec 2017 | $10.05 M(+109.5%) | $10.05 M(+18.0%) |
Sep 2017 | - | $8.52 M(+32.4%) |
Jun 2017 | - | $6.44 M(+9.0%) |
Mar 2017 | - | $5.91 M(+23.0%) |
Dec 2016 | $4.80 M(-90.3%) | $4.80 M(+22.6%) |
Sep 2016 | - | $3.92 M(+16.4%) |
Jun 2016 | - | $3.36 M(-61.1%) |
Mar 2016 | - | $8.64 M(-82.5%) |
Dec 2015 | $49.28 M(+38.7%) | $49.28 M(+60.8%) |
Sep 2015 | - | $30.64 M(-5.9%) |
Jun 2015 | - | $32.56 M(-2.1%) |
Mar 2015 | - | $33.25 M(-6.4%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2014 | $35.54 M(-22.9%) | $35.54 M(-11.0%) |
Sep 2014 | - | $39.93 M(-4.8%) |
Jun 2014 | - | $41.95 M(-4.6%) |
Mar 2014 | - | $43.96 M(-4.7%) |
Dec 2013 | $46.11 M(+65.0%) | $46.11 M(+9.7%) |
Sep 2013 | - | $42.05 M(+9.3%) |
Jun 2013 | - | $38.49 M(+3.8%) |
Mar 2013 | - | $37.10 M(+32.7%) |
Dec 2012 | $27.95 M(+1.5%) | $27.95 M(+9.9%) |
Sep 2012 | - | $25.42 M(-4.8%) |
Jun 2012 | - | $26.70 M(+2.4%) |
Mar 2012 | - | $26.07 M(-5.4%) |
Dec 2011 | $27.55 M(-9.9%) | $27.55 M(-5.9%) |
Sep 2011 | - | $29.29 M(+0.4%) |
Jun 2011 | - | $29.18 M(-2.1%) |
Mar 2011 | - | $29.82 M(-2.5%) |
Dec 2010 | $30.59 M(+27.5%) | $30.59 M(-3.3%) |
Sep 2010 | - | $31.62 M(+85.7%) |
Jun 2010 | - | $17.03 M(-11.1%) |
Mar 2010 | - | $19.15 M(-20.2%) |
Dec 2009 | $24.00 M(-84.6%) | $24.00 M(-10.2%) |
Sep 2009 | - | $26.73 M(-83.0%) |
Jun 2009 | - | $156.77 M(-9.3%) |
Mar 2009 | - | $172.88 M(+10.8%) |
Dec 2008 | $156.04 M(+59.6%) | $156.04 M(+24.5%) |
Sep 2008 | - | $125.37 M(+28.9%) |
Jun 2008 | - | $97.27 M(+1.4%) |
Mar 2008 | - | $95.92 M(-1.9%) |
Dec 2007 | $97.75 M(+72.9%) | $97.75 M(+477.0%) |
Sep 2007 | - | $16.94 M(-11.5%) |
Jun 2007 | - | $19.14 M(+22.2%) |
Mar 2007 | - | $15.66 M(-72.3%) |
Dec 2006 | $56.54 M(+201.8%) | $56.54 M(+1.0%) |
Sep 2006 | - | $55.99 M(+198.9%) |
Dec 2005 | $18.73 M(+33.2%) | $18.73 M(+7.6%) |
Mar 2005 | - | $17.41 M |
Dec 2004 | $14.06 M(+302.3%) | - |
Dec 2003 | $3.50 M(>+9900.0%) | - |
Dec 2001 | $29.00 K | - |
FAQ
- What is Madrigal Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual total liabilities year-on-year change?
- What is Madrigal Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly total liabilities year-on-year change?
What is Madrigal Pharmaceuticals annual total liabilities?
The current annual total liabilities of MDGL is $235.21 M
What is the all time high annual total liabilities for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual total liabilities is $235.21 M
What is Madrigal Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, MDGL annual total liabilities has changed by +$70.03 M (+42.40%)
What is Madrigal Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of MDGL is $296.11 M
What is the all time high quarterly total liabilities for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly total liabilities is $296.11 M
What is Madrigal Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, MDGL quarterly total liabilities has changed by +$53.44 M (+22.02%)